Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil.
Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to US$ 0.86 million (US$ 0.281057 to 1 Brazilian Real exchange rate on February 4, 2003). The first shipment to Itaca marks the launch of Dragon’s EPO into the Brazilian market.
“This order followed an audit in 2002 by the Brazilian Health Authority (“ANVISA? inspectors of Dragon’s production facility in Nanjing, China. The ANVISA audit has provided valuable feedback to the Nanjing staff as well as the Vancouver management. We have been implementing the necessary steps to elevate our facility to the highest technical and documentary standards expected for today’s biotechnology industry anywhere in the world with the help of international experts” said Dr. Alexander Wick, President of Dragon Pharmaceuticals Inc.
“Our first order in Brazil demonstrates our commitment to expanding sales into new international markets outside of China,” said Dr. Wick, “We have secured licensing agreements with fourteen distribution partners covering more than ninety countries globally and we expect to receive additional product registration approvals throughout the year.”
Find Dragon Pharma Steroids
163 total views, 2 today